Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003021815 | SCV003319319 | pathogenic | Bardet-Biedl syndrome | 2022-02-19 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with BBS4-related conditions. This sequence change creates a premature translational stop signal (p.Glu432Glyfs*10) in the BBS4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS4 are known to be pathogenic (PMID: 11381270, 12016587, 20177705, 27894351). |
Baylor Genetics | RCV003459700 | SCV004214078 | likely pathogenic | Bardet-Biedl syndrome 4 | 2023-12-28 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV003459700 | SCV005630910 | likely pathogenic | Bardet-Biedl syndrome 4 | 2024-04-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004750249 | SCV005343200 | likely pathogenic | BBS4-related disorder | 2024-09-20 | no assertion criteria provided | clinical testing | The BBS4 c.1294dupG variant is predicted to result in a frameshift and premature protein termination (p.Glu432Glyfs*10). To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. Frameshift variants in BBS4 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |